Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury

Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Liu, Y., Yang, Y., Zhang, C., Huang, F., Wang, F., Yuan, J., Wang, Z., Li, J., Li, J., Feng, C., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1643-8 · Cited by 2,056

Status of Hypertension in China: Results From the China Hypertension Survey, 2012–2015

Wang, Z., Chen, Z., Zhang, L., Wang, X., Hao, G., Zhang, Z., Shao, L., Tian, Y., Dong, Y., Zheng, C., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032380 · Cited by 1,698

Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2951-z · Cited by 715

Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury

Yang, P., Gu, H., Zhao, Z., Wang, W., Cao, B., Lai, C., Yang, X., Zhang, L., Duan, Y., Zhang, S., et al. (2014) · Scientific Reports · doi:10.1038/srep07027 · Cited by 283

ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway

Ye, R., & Liu, Z. (2019) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2019.104350 · Cited by 205

Beta Blocker and Angiotensin-Converting Enzyme Inhibitor Therapy Is Associated with Decreased Th1/Th2 Cytokine Ratios and Inflammatory Cytokine Production in Patients with Chronic Heart Failure

Gage, J. R., Fonarow, G. C., Hamilton, M. A., Widawski, M., Martı́nez-Maza, O., & Vredevoe, D. L. (2004) · NeuroImmunoModulation · doi:10.1159/000076766 · Cited by 81

Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension

Moon, J.-Y. (2013) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2013.11.2.41 · Cited by 81

Cardiovascular Damage in COVID-19: Therapeutic Approaches Targeting the Renin-Angiotensin-Aldosterone System

Lumpuy‐Castillo, J., Lorenzo-Almorós, A., Lázaro, A. M. P., Sánchez‐Ferrer, C. F., Egido, J., Tuñón, J., Peiró, C., & Lorenzo, Ó. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186471 · Cited by 26

Severe Acute Respiratory Syndrome–Associated Coronavirus 2 Infection and Organ Dysfunction in the ICU: Opportunities for Translational Research

Verhoef, P. A., Kannan, S., Sturgill, J., Tucker, E. W., Morris, P. E., Miller, A. C., Sexton, T. R., Koyner, J. L., Hejal, R. B., Brakenridge, S. C., et al. (2021) · Critical Care Explorations · doi:10.1097/cce.0000000000000374 · Cited by 25

Molecular Epidemiology of SARS-CoV-2: The Dominant Role of Arginine in Mutations and Infectivity

Ridgway, H. F., Ntallis, C., Chasapis, C. T., Kelaidonis, K., Matsoukas, M., Plotas, P., Apostolopoulos, V., Moore, G. J., Tsiodras, S., Paraskevis, D. N., et al. (2023) · Viruses · doi:10.3390/v15020309 · Cited by 25

COVID-19: what are the risks in hypertensive patients?

Коростовцева, Л. С., Rotar, О. P., & Конради, А. О. (2020) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2020-26-2-124-132 · Cited by 25

Renin-angiotensin system inhibition in COVID-19 patients

de Vries, A. A. F. (2020) · Netherlands Heart Journal · doi:10.1007/s12471-020-01439-5 · Cited by 27

A systematic review and meta‐analysis of the use of renin‐angiotensin system drugs and COVID‐19 clinical outcomes: What is the evidence so far?

Kurdi, A. B., Abutheraa, N., Akil, L., & Godman, B. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.666 · Cited by 24

Renin-angiotensin system blocker and outcomes of COVID-19: a systematic review and meta-analysis

Lee, H. W., Yoon, C., Jang, E. J., & Lee, C. (2021) · Thorax · doi:10.1136/thoraxjnl-2020-215322 · Cited by 24

Potential Role of Gut Microbiota in Traditional Chinese Medicine against COVID-19

Zhang, Q., Yue, S., Wang, W., Chen, Y., Zhao, C., Song, Y., Yan, D., Zhang, L., & Tang, Y. (2021) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x21500373 · Cited by 24

Discovery of Small-Molecule Inhibitors of SARS-CoV-2 Proteins Using a Computational and Experimental Pipeline

Lau, E. Y., Negrete, O. A., Bennett, W. F., Bennion, B. J., Borucki, M. K., Bourguet, F. A., Epstein, A., Franco, M., Harmon, B., He, S., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.678701 · Cited by 24

Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity

Spini, A., Giudice, V., Brancaleone, V., Morgese, M. G., Francia, S. D., Filippelli, A., Ruggieri, A., Ziche, M., Ortona, E., Cignarella, A., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105848 · Cited by 26

Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors

Golpe, R., Pérez‐de‐Llano, L. A., Dacal-Rivas, D., Guerrero-Sande, H., Vide, B. P., & Ventura-Valcárcel, P. (2020) · Medicina Clínica · doi:10.1016/j.medcli.2020.06.013 · Cited by 24

Downregulation of ACE, AGTR1, and ACE2 Genes Mediating SARS-CoV-2 Pathogenesis by Gut Microbiota Members and Their Postbiotics on Caco-2 Cells

Badi, S. A., Malek, A., Paolini, A., Masoumi, M. R., Seyedi, S. A., Amanzadeh, A., Masotti, A., Khatami, S., & Siadat, S. D. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105798 · Cited by 26

Genetically Engineered Live-Attenuated Middle East Respiratory Syndrome Coronavirus Viruses Confer Full Protection against Lethal Infection

Gutierrez-Alvarez, F. J., Honrubia, J. M., Fernández‐Delgado, R., Wang, L., Castaño-Rodríguez, C., Zúñiga, S., Sola, I., & Enjuanes, L. (2021) · mBio · doi:10.1128/mbio.00103-21 · Cited by 24

Association of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers with risk of mortality, severity or SARS-CoV-2 test positivity in COVID-19 patients: meta-analysis

Biswas, M., & Kali, M. S. K. (2021) · Scientific Reports · doi:10.1038/s41598-021-84678-9 · Cited by 24

Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting

Subbarao, S. A. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00796-w · Cited by 24

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19

Moore, G. J., Pires, J. M., Kelaidonis, K., Gadanec, L. K., Zulli, A., Apostolopoulos, V., & Matsoukas, J. (2021) · Biomolecules · doi:10.3390/biom11070979 · Cited by 23

Impact of renin–angiotensin–aldosterone system inhibitors on COVID-19

Matsuzawa, Y., Kimura, K., Ogawa, H., & Tamura, K. (2022) · Hypertension Research · doi:10.1038/s41440-022-00922-3 · Cited by 23

Long-term outcomes of COVID-19 convalescents: An 18.5-month longitudinal study in Wuhan

Guo, Y., Wang, H., Xiao, M., Guan, X., Lei, Y., Diao, T., Long, P., Zeng, R., Lai, X., Cai, H., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.12.008 · Cited by 23

Effective prognostic and clinical risk stratification in COVID‐19 using multimodality biomarkers

Liu, A., Hammond, R., Donnelly, P., Kaski, J. C., & Coates, A. R. M. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13646 · Cited by 24

State-of-the-Art review: Hypertension practice guidelines in the era of COVID-19

Ferdinand, K. C., Vo, T. N., & Echols, M. R. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100038 · Cited by 25

The renin–angiotensin–aldosterone system: Role in pathogenesis and potential therapeutic target in COVID‐19

Braga, C. L., Silva-Aguiar, R. P., Battaglini, D., Peruchetti, D. B., Robba, C., Pelosi, P. P., Rocco, P. R. M., Caruso‐Neves, C., & Silva, P. L. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.623 · Cited by 22

Role of the renin-angiotensin system in the development of severe COVID-19 in hypertensive patients

Silva-Aguiar, R. P., Peruchetti, D. B., Rocco, P. R. M., Schmaier, A. H., Silva, P., Martins, M. A., Carvalho, V. F., Pinheiro, A. A. S., & Caruso‐Neves, C. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00286.2020 · Cited by 22

Effects of ACEI and ARB on COVID-19 patients: A meta-analysis

Xue, Y., Sun, S., Cai, J., Zeng, L., Wang, S., Wang, S., Li, J., Sun, L., & Huo, J. (2020) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320320981321 · Cited by 22

Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic

Gressens, S. B., Lefthériotis, G., Dussaule, J., Flamant, M., Levy, B. I., & Vidal‐Petiot, E. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.624052 · Cited by 22

Classical and Counter-Regulatory Renin–Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology

Almutlaq, M., Alamro, A. A., Alroqi, F. J., & Barhoumi, T. (2021) · CJC Open · doi:10.1016/j.cjco.2021.04.004 · Cited by 24

Expression of SARS-CoV-2 receptor “ACE2” in human pancreatic β cells: to be or not to be!

El‐Huneidi, W., Hamad, M. A., & Taneera, J. (2021) · Islets · doi:10.1080/19382014.2021.1954458 · Cited by 25

An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection

Devaux, C. A., & Camoin-Jau, L. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1042200 · Cited by 20

Translating bioactive peptides for COVID-19 therapy

Bhullar, K. S., Drews, S. J., & Wu, J. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173661 · Cited by 21

Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID-19 mortality: a retrospective cohort study

Yahyavi, A., Hemmati, N., Derakhshan, P., Banivaheb, B., Behnagh, A. K., Tofighi, R., TehraniYazdi, A., & Kabir, A. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02523-9 · Cited by 21

Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors

Lee, T., Cau, A., Cheng, M. P., Levin, A., Lee, T. C., Vinh, D. C., Lamontagne, F., Singer, J., Walley, K. R., Murthy, S., et al. (2021) · CJC Open · doi:10.1016/j.cjco.2021.03.001 · Cited by 21

Acute cerebrovascular accidents associated with SARS-CoV-2 coronavirus infection (COVID-19)

Putilina, M. V., Vechorko, V. I., Grishin, D. V., & Sidel’nikova, L. V. (2020) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2020120121109 · Cited by 22

COVID ‐19 and renin angiotensin aldosterone system: Pathogenesis and therapy

Babajani, F., Kakavand, A., Mohammadi, H., Sharifi, A., Zakeri, S., Asadi, S., Afshar, Z. M., Rahimi, Z., & Sayad, B. (2021) · Health Science Reports · doi:10.1002/hsr2.440 · Cited by 20

Association of renin‐angiotensin‐aldosterone system inhibitors with mortality and testing positive of COVID‐19: Meta‐analysis

Yokoyama, Y., Aikawa, T., Takagi, H., Briasoulis, Α., & Kuno, T. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26588 · Cited by 19

The Intersection between COVID-19, the Gene Family of ACE2 and Alzheimer’s Disease

Haghighi, M. M., Kakhki, E. G., Sato, C., Ghani, M., & Rogaeva, E. A. (2020) · Neuroscience Insights · doi:10.1177/2633105520975743 · Cited by 20

Clinical Characteristics and Outcomes of Patients with COVID-19 Infection: The Results of the SARS-RAS Study of the Italian Society of Hypertension

SARS-RAS Investigator Group, Mancusi, C., Grassi, G. M., Borghi, C., Ferri, C., Muiesan, M. L., Volpe, M., & Iaccarino, G. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-020-00429-3 · Cited by 20

Effects of COVID-19 on Arrhythmia

Zhan, Y., Yue, H., Liang, W., & Wu, Z. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9090292 · Cited by 21

Double trouble: combined cardiovascular effects of particulate matter exposure and coronavirus disease 2019

Tanwar, V., Adelstein, J. M., & Wold, L. E. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa293 · Cited by 21

Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study

Maldonado, V., Hernández-Ramírez, C., Oliva-Pérez, E. A., Sánchez-Martínez, C. O., Pimentel-González, J. F., Molina-Sánchez, J. R., Jiménez-Villalba, Y. Z., Chávez, J., & Loza-Mejía, M. A. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107209 · Cited by 21

From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy

Matsoukas, J., Apostolopoulos, V., Zulli, A., Moore, G. J., Kelaidonis, K., Moschovou, K., & Mavromoustakos, T. (2021) · Molecules · doi:10.3390/molecules26030618 · Cited by 20

Clinical and laboratory factors associated with coronavirus disease 2019 (Covid‐19): A systematic review and meta‐analysis

Minh, L. H. N., Abozaid, A. A., Ha, N. X., Quang, L. L., Gad, A. G., Tiwari, R., Le, T., Quyen, D. T. K., AL-Manaseer, B. M., Nguyen, D. K., et al. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2288 · Cited by 18

Counter-regulatory renin-angiotensin system in hypertension: review and update in the era of COVID-19 pandemic

Chen, H., Peng, J., Wang, T., Wen, J., Chen, S., Huang, Y., & Zhang, Y. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115370 · Cited by 19

Impacto de los inhibidores de la enzima de conversión de la angiotensina y los antagonistas del receptor de la angiotensina II en la COVID-19 en una población occidental. Registro CARDIOVID

López‐Otero, D., López‐País, J., Antonio, C. E. C., Muiños, P. J. A., González-Ferrero, T., Pérez-Poza, M., García, Ó. O., Díaz‐Fernández, B., Bastos-Fernández, M., Bouzas‐Cruz, N., et al. (2020) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.05.030 · Cited by 19

Association between renin–angiotensin–aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment

Lahens, A., Mullaert, J., Gressens, S. B., Gault, N., Flamant, M., Deconinck, L., Joly, V., Yazdanpanah, Y., Lescure, F.-X., & Vidal‐Petiot, E. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002658 · Cited by 19

ACE inhibition and cardiometabolic risk factors, lung ACE2 and TMPRSS2 gene expression, and plasma ACE2 levels: a Mendelian randomization study

Gill, D., Arvanitis, M., Carter, P., Cordero, A. I. H., Jo, B., Karhunen, V., Larsson, S. C., Li, X., Lockhart, S. M., Mason, A. M., et al. (2020) · Royal Society Open Science · doi:10.1098/rsos.200958 · Cited by 20

Severity of COVID-19 infection in ACEI/ARB users in specialty hospitals: A retrospective cohort study

Alrashed, A. A., Khan, T. M., Alhusseini, N. K., Asdaq, S. M. B., Enani, M. A., Alosaimi, B., Alkhani, N., Mohzari, Y. A., Alghalbi, M., Alfahad, W. A., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.03.004 · Cited by 19

Renin–Angiotensin–Aldosterone Inhibitors and COVID-19 Infection

Tsampasian, V., Corballis, N. H., & Vassiliou, V. S. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01207-3 · Cited by 19

Renin–angiotensin system inhibition and risk of infection and mortality in COVID‐19: a systematic review and meta‐analysis

Koshy, A. N., Murphy, A. C., Farouque, O., Ramchand, J., Burrell, L. M., & Yudi, M. (2020) · Internal Medicine Journal · doi:10.1111/imj.15002 · Cited by 19

Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study

de Abajo, F. J., Rodríguez-Miguel, A., Rodríguez‐Martín, S., Lerma, V., García‐Lledó, A., on behalf of MED-ACE2-COVID19 Study Group, de Abajo, F. J., Rodríguez-Miguel, A., Rodríguez‐Martín, S., Lerma, V., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-01992-9 · Cited by 21

Beyond dexamethasone, emerging immuno‐thrombotic therapies for COVID‐19

Jensen, M. P., George, M., Gilroy, D., & Sofat, R. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14540 · Cited by 17

COMDORA-SBN recommendations for patients with rare kidney diseases in relation to the Covid-19 pandemic

Colares, V. S., Miranda, S. M. C., de Andrade, L. G. M., Palma, L. M. P., de Castro, M. C. R., Silva, C. A. B., Penido, M. G. M. G., Sobral, R. M. L., & Vaisbich, M. H. (2020) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2020-s109 · Cited by 18

Which ones, when and why should renin-angiotensin system inhibitors work against COVID-19?

Montanari, M., Canonico, B., Nordi, E., Vandini, D., Barocci, S., Benedetti, S., Carlotti, E., & Zamai, L. (2021) · Advances in Biological Regulation · doi:10.1016/j.jbior.2021.100820 · Cited by 19

Rosemary and its protective potencies against COVID-19 and other cytokine storm associated infections: A molecular review

Shiravi, A., Akbari, A., Mohammadi, Z. S., Khalilian, M. S., Zeinalian, A., & Zeinalian, M. (2021) · Mediterranean Journal of Nutrition and Metabolism · doi:10.3233/mnm-210013 · Cited by 19

Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial

Macedo, A. V. S., Silva, P. G. M. D. B. E., de Paula, T. C., Moll-Bernardes, R. J., dos Santos, T. M., Barbosa, L. M., Feldman, A., Arruda, G. D. S., de Albuquerque, D. C., de Sousa, A. S., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.04.001 · Cited by 18

Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection

Salah, H. M., Calcaterra, G., & Mehta, J. L. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420947628 · Cited by 18

Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19

Megaly, M. S., & Glogoza, M. (2020) · Scottish Medical Journal · doi:10.1177/0036933020949219 · Cited by 18

Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19

Sinha, S., Sehgal, A., & Sehgal, R. (2020) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2020.03064 · Cited by 18

Impact of antihypertensive agents on clinical course and in-hospital mortality: analysis of 169 hypertensive patients hospitalized for COVID-19

Kocayiğit, İ., Kocayiğit, H., Yaylacı, S., Can, Y., Erdem, A. F., & Karabay, O. (2020) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.66.s2.71 · Cited by 38

Metabolic syndrome and COVID-19

Matias, J. N., Campanari, G. S. D. S., de Souza, G. A., Lima, V. M., Tofano, R. J., Detregiachi, C. R. P., & Barbalho, S. (2020) · AIMS Bioengineering · doi:10.3934/bioeng.2020021 · Cited by 34

Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Mortality Among COVID-19 Patients: A Systematic Review and Meta-Analysis

Kashour, T. S., Abdulhak, A. A. B., Tlayjeh, H., Hassett, L. C., Noman, A. T., Mohsen, A., Al-Mallah, M. H., & Tleyjeh, I. M. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001281 · Cited by 18

Association of In-hospital Use of Statins, Aspirin, and Renin-Angiotensin-Aldosterone Inhibitors with Mortality and ICU Admission Due to COVID-19

Vahedian‐Azimi, A., Rahimi‐Bashar, F., Najafi, A., Kidde, J., Shahriary, A., Shojaei, S., Pourhoseingholi, M. A., Jamialahmadi, T., & Sahebkar, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-71697-4_17 · Cited by 17

Hypertension and mortality in SARS-COV-2 infection: A meta-analysis of observational studies after 2 years of pandemic

D’Elia, L., Giaquinto, A., Zarrella, A. F., Rendina, D., Idelson, P. I., Strazzullo, P., & Galletti, F. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.11.018 · Cited by 17

Ketogenic Diet and Ketone Bodies as Clinical Support for the Treatment of SARS-CoV-2—Review of the Evidence

Bolesławska, I., Kowalówka, M., Bolesławska-Król, N., & Przysławski, J. (2023) · Viruses · doi:10.3390/v15061262 · Cited by 18

Novel benzimidazole angiotensin receptor blockers with anti-SARS-CoV-2 activity equipotent to that of nirmatrelvir: computational and enzymatic studies

Ridgway, H. F., Moore, G. J., Gadanec, L. K., Zulli, A., Apostolopoulos, V., Hoffmann, W., Wegrzyn, K. E., Vassilaki, N., Mpekoulis, G., Zouridakis, M., et al. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2362675 · Cited by 17

Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors

Golpe, R., Pérez‐de‐Llano, L. A., Dacal-Rivas, D., Guerrero-Sande, H., Vide, B. P., & Ventura-Valcárcel, P. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.06.028 · Cited by 17

An Overview of the Temporal Shedding of SARS-CoV-2 RNA in Clinical Specimens

Zhurakivska, K., Troiano, G., Pannone, G., Caponio, V. C. A., & Muzio, L. L. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.00487 · Cited by 17

Lock, Stock and Barrel: Role of Renin-Angiotensin-Aldosterone System in Coronavirus Disease 2019

Zanza, C., Tassi, M. F., Romenskaya, T., Piccolella, F., Abenavoli, L., Franceschi, F., Piccioni, A., Ojetti, V., Saviano, A., Canonico, B., et al. (2021) · Cells · doi:10.3390/cells10071752 · Cited by 17

Comparative Survival Analysis of Immunomodulatory Therapy for COVID-19 'Cytokine Storm': A Retrospective Observational Cohort StudyPreprint

Narain, S., Stefanov, D. G., Chau, A. S., Weber, A. G., Marder, G. S., Kaplan, B. M., Malhotra, P., Bloom, O., Liu, A., LESSER, M. L., et al. (2020) · SSRN Electronic Journal · doi:10.1101/2020.06.16.20126714 · Cited by 17

Pharmacological treatment of COVID-19: lights and shadows

Menzella, F., Biava, M., Barbieri, C., Livrieri, F., & Facciolongo, N. C. (2020) · Drugs in Context · doi:10.7573/dic.2020-4-6 · Cited by 16

Mortality and use of angiotensin-converting enzyme inhibitors in COVID 19 disease: a systematic review

Nunes, J. P. L. (2020) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000085 · Cited by 16

Antiplatelet therapy in patients with Covid-19: A retrospective observational study

Banik, J., Mezera, V., Köhler, C., & Schmidtmann, M. (2020) · Thrombosis Update · doi:10.1016/j.tru.2020.100026 · Cited by 16

Male bias in ACE2 basic science research: missed opportunity for discovery in the time of COVID-19

Stanić, B. M., Maddox, S., de Souza, A. M. A., Wu, X., Mehranfard, D., Ji, H., Speth, R. C., & Sandberg, K. L. (2021) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00356.2020 · Cited by 15

Bihemispheric ischemic strokes in patients with COVID-19

Kurian, C., Mayer, S. A., Kaur, G., Sahni, R., Feldstein, E., Samaan, M., Viswanathan, D., Sami, T., Ali, S. F., Alshammari, H., et al. (2022) · Brain Circulation · doi:10.4103/bc.bc_65_21 · Cited by 16

Sacubitril/valsartan alleviates sepsis‐induced acute lung injury via inhibiting GSDMD ‐dependent macrophage pyroptosis in mice

Wang, J., Li, J., Lou, A., Lin, Y. H., Xu, Q., Cui, W., Huang, W., Wang, G., Li, Y., Sun, J., et al. (2022) · FEBS Journal · doi:10.1111/febs.16696 · Cited by 16

Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19

Huang, N. X., Yuan, Q., Fang, F., Yan, B. P., & Sanderson, J. E. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280280 · Cited by 16

Role of renin-angiotensin system/angiotensin converting enzyme-2 mechanism and enhanced COVID-19 susceptibility in type 2 diabetes mellitus

Shukla, A. K., Awasthi, K., Usman, K., & Banerjee, M. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i4.606 · Cited by 17

A Review on Currently Available Potential Therapeutic Options for COVID-19

Moghadam, S. O. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s263666 · Cited by 20

The fight against COVID-19: Striking a balance in the renin–angiotensin system

Dean, A. Q., Bozza, W. P., Twomey, J. D., Luo, S., Nalli, A. D., & Zhang, B. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.04.006 · Cited by 16

COVID-19 and metabolic comorbidities: An update on emerging evidences for optimal therapies

Hua, S., Yang, Y., Zou, D., Li, J., Yan, K., Xu, Y., Jiang, X. X., Rong, X., & Ye, D. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111685 · Cited by 16

Computational identification of repurposed drugs against viruses causing epidemics and pandemics via drug-target network analysis

Rajput, A., Thakur, A., Rastogi, A., Choudhury, S., & Kumar, M. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104677 · Cited by 16

Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all‐cause mortality and other clinical outcomes in patients with confirmed COVID‐19: A systemic review and meta‐analysis

Jia, N., Zhang, G., Sun, X., Wang, Y., Zhao, S., Chi, W., Dong, S., Xia, J., Zeng, P., & Liu, D. (2021) · Journal of Clinical Hypertension · doi:10.1111/jch.14329 · Cited by 16

Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells

Iwanski, J. B., Kazmouz, S. G., Li, S., Stansfield, B. N., Salem, T. T., Perez‐Miller, S., Kazui, T., Jena, L., Uhrlaub, J. L., Lick, S. D., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.08.018 · Cited by 16

Cardiovascular, cerebrovascular, and renal co-morbidities in COVID-19 patients: A systematic-review and meta-analysis

Lee, A. C., Li, W. T., Apostol, L., Ma, J., Taub, P. R., Chang, E. Y., Rajasekaran, M. R., & Ongkeko, W. M. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.06.038 · Cited by 16

Effects of Statins on Renin–Angiotensin System

Kiaie, N., Gorabi, A. M., Reiner, Ž., Jamialahmadi, T., Ruscica, M., & Sahebkar, A. (2021) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd8070080 · Cited by 17

Obesity and COVID-19: the ominous duet affecting the renin-angiotensin system

Livio, L. U. Z. I., Bucciarelli, L. G., FERRULLI, A., Terruzzi, I., & MASSARINI, S. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.20.03402-1 · Cited by 15

Risk factors for the delayed viral clearance in COVID‐19 patients

Chen, X., Hu, W., Yang, M., Ling, J., Zhang, Y., Deng, L., Li, J., Lundkvist, Å., Lindahl, J. F., & Xiong, Y. (2021) · Journal of Clinical Hypertension · doi:10.1111/jch.14308 · Cited by 15

Sequelae and Comorbidities of COVID-19 Manifestations on the Cardiac and the Vascular Systems

Batta, Y., King, C., Johnson, J. B., Haddad, N., Boueri, M. G., & Haddad, G. E. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.748972 · Cited by 14

Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System

Moore, G. J., Ridgway, H. F., Kelaidonis, K., Chasapis, C. T., Ligielli, I., Mavromoustakos, T., Bojarska, J., & Matsoukas, J. (2022) · Molecules · doi:10.3390/molecules27154854 · Cited by 15

Unraveling the Underlying Molecular Mechanism of ‘Silent Hypoxia’ in COVID-19 Patients Suggests a Central Role for Angiotensin II Modulation of the AT1R-Hypoxia-Inducible Factor Signaling Pathway

Devaux, C. A., & Lagier, J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062445 · Cited by 15

Preeclampsia in the Context of COVID‐19: Mechanisms, Pathophysiology, and Clinical Outcomes

Nobrega, G. D. M., Jones, B. R., Mysorekar, I. U., & Costa, M. L. (2024) · American Journal of Reproductive Immunology · doi:10.1111/aji.13915 · Cited by 16

Diabetes mellitus e hipertensión arterial como factor de riesgo de mortalidad en pacientes con Covid-19

Mejía, P. J. N., Lizaraso-Soto, F., Velasco-Guerrero, J. C., & Loro-Chero, L. M. (2021) · Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo · doi:10.35434/rcmhnaaa.2020.134.766 · Cited by 15

Global interventions in hypertension: new and emerging concepts

Ferdinand, K. C., Reddy, T. K., & Vo, T. N. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000866 · Cited by 16

Implications for Systemic Approaches to COVID-19: Effect Sizes of Remdesivir, Tocilizumab, Melatonin, Vitamin D3, and Meditation

Castle, R., Williams, M. A., Bushell, W. C., Rindfleisch, J. A., Peterson, C. T., Marzolf, J. R., Brouwer, K. C., & Mills, P. J. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s323356 · Cited by 15

Prevalence of comorbidities in deceased patients with COVID-19: A systematic review

Justino, D. C. P., Silva, D. F. O., Costa, K. T. D. S., de Morais, T. N. B., & de Andrade, F. B. (2022) · Medicine · doi:10.1097/md.0000000000030246 · Cited by 15

Comparison of renin–angiotensin–aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes

Bezabih, Y. M., Bezabih, A., Alamneh, E. A., Peterson, G. M., & Bezabhe, W. M. M. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06088-6 · Cited by 14

Update Alert 7: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults

Mackey, K., Kansagara, D. L., & Vela, K. (2021) · Annals of Internal Medicine · doi:10.7326/l20-1446 · Cited by 14

Computational and Enzymatic Studies of Sartans in SARS-CoV-2 Spike RBD-ACE2 Binding: The Role of Tetrazole and Perspectives as Antihypertensive and COVID-19 Therapeutics

Kelaidonis, K., Ligielli, I., Letsios, S., Vidali, V. P., Mavromoustakos, T., Vassilaki, N., Moore, G. J., Hoffmann, W., Wegrzyn, K. E., Ridgway, H. F., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098454 · Cited by 14

Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study

Kim, J. H., Baek, Y., Lee, H., Choe, Y. J., Shin, H. J., & Shin, J. (2020) · Epidemiology and Health · doi:10.4178/epih.e2021004 · Cited by 14

Possible Benefits of Zinc supplement in CVD and COVID-19 Comorbidity

Karim, M. M., Sultana, S., Sultana, R., & Rahman, M. T. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.09.022 · Cited by 14

An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19

Rao, G. K., Gowthami, B., Naveen, N. R., & Samudrala, P. K. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100063 · Cited by 14

Therapeutics and Vaccines: Strengthening Our Fight Against the Global Pandemic COVID-19

Bhattacharjee, A., Saha, M., Halder, A., Debnath, A., & Mukherjee, O. (2021) · Current Microbiology · doi:10.1007/s00284-020-02310-x · Cited by 14

Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic.

Dworakowska, D., & Grossman, A. B. (2020) · PubMed · doi:10.26402/jpp.2020.2.01 · Cited by 12

Use of inhibitors of the renin‐angiotensin system in hypertensive patients and COVID‐19 severity: A systematic review and meta‐analysis

Barochiner, J., & Martínez, R. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13246 · Cited by 56

Comparison of Renin–Angiotensin–Aldosterone System Inhibitors with Other Antihypertensives in Association with Coronavirus Disease-19 Clinical Outcomes: Systematic Review and Meta-AnalysisPreprint

Bezabih, Y. M., Bezabih, A., Alamneh, E. A., Peterson, G. M., & Bezabhe, W. M. M. (2020) · Preprints.org · doi:10.20944/preprints202005.0392.v1

Effect of Renin-Angiotensin-Aldosterone System inhibitors on outcomes of COVID-19 patients with hypertension: Systematic review and Meta-analysisPreprint

Beressa, T. B., Sahilu, T., & Deyno, S. (2020) · medRxiv · doi:10.1101/2020.09.03.20187393 · Cited by 4

[Differences among renin-angiotensin system inhibitor drugs in prognosis of hypertense patients with COVID-19].

Caamaño, M. N., Rio, J. M., Nieto-Sandoval-Martín-de-la-Sierra, P., Águila‐Gordo, D., Mateo-Gómez, C., Rodríguez-Martínez, M., Salas-Bravo, D., & Piqueras‐Flores, J. (2022) · PubMed Central · doi:10.24875/acm.21000185